Therefore, early supplementation with SGLT2 inhibitors may be preferable to DPP-4 inhibitors to provide early cardiac protection and primary prevention of CVD in patients with early-stage T2DM and preserved cardiac function. Here, SLC5A2 is linked to type 2 diabetes mellitus.